New Cousteau-Linked...
Health Care: Drugs
Array BioPharma Inc. (ARRY: NASDAQ)
$3.38 -0.04 | -1.17%
06/04/12 - 04:00 PM ET
Company Balance Sheet
| Jun 2011 | Jun 2010 | Jun 2009 | Jun 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 48.10M | 32.85M | 33.20M | 56.45M |
| Receivables | 0.00 | 0.00 | 0.00 | 39.24M |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 70.56M | 117.30M | 44.92M | 100.75M |
| Property, Plant & Equipment, Gross | 85.97M | 84.18M | 83.68M | 80.88M |
| Accumulated Depreciation & Depletion | 70.27M | 62.76M | 57.18M | 50.72M |
| Property, Plant & Equipment, Net | 15.70M | 21.41M | 26.50M | 30.16M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 3.11M | 20.47M | 23.64M | 32.16M |
| Total Non-Current Assets | 18.81M | 41.88M | 50.14M | 62.32M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 89.37M | 159.18M | 95.06M | 163.08M |
| Accounts Payable | 4.46M | 5.63M | 6.48M | 4.66M |
| Short Term Debt | 150.00K | 0.00 | 15.00M | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 2.72M |
| Total Current Liabilities | 69.81M | 77.93M | 50.30M | 34.41M |
| Long Term Debt | 91.39M | 112.82M | 68.17M | 35.36M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 59.03M | 85.10M | 50.29M | 55.29M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 150.42M | 197.93M | 118.46M | 90.64M |
| Total Liabilities | 220.23M | 275.86M | 168.76M | 125.05M |
| Preferred Stock Equity | 30.00M | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | -160.86M | -116.68M | -73.70M | 38.03M |
| Common Par | 57.00K | 53.00K | 48.00K | 48.00K |
| Additional Paid In Capital | 346.85M | 332.28M | 312.35M | 304.71M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -547.16M | -490.83M | -413.20M | -285.39M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 39.39M | 41.82M | 27.10M | 18.65M |
| Total Capitalization | -39.47M | -3.85M | -5.53M | 73.38M |
| Total Equity | -130.86M | -116.68M | -73.70M | 38.03M |
| Total Liabilities & Stock Equity | 89.37M | 159.18M | 95.06M | 163.08M |
| Total Common Shares Outstanding | 57.02M | 53.22M | 48.13M | 47.54M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 55.45M | 50.22M | 47.84M | 47.31M |
| Diluted Weighted Shares Outstanding | 55.45M | 50.22M | 47.84M | 47.31M |
| Number of Employees | 259 | 340 | 355 | 386 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with ARRY
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks Under-$10 Moving Hig...
- ContributorUnder-$10 Setting Up To Tra...
- UserASCO 2010
- ContributorBarron's Activist Stocks 1-...
- UserPART 6 JPMorgan 28th Annual...
- ContributorBarron's Activist Stocks 1-...
- ContributorBarron's Activist Stocks 1-...
Latest ARRY Headlines from TheStreet
- ASCO 2012 Live Blog -- Monday 06.04.12 | 06:06 am
- Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer 05.25.12 | 05:05 am
- The Next Big Thing in Biotech: ASCO Conference
05.25.12 | 05:05 am - 7 Stocks Under $10 Making Big Moves 05.17.12 | 12:05 pm
- Biotech Stock Live Chat Recap: ASCO & Obesity 05.17.12 | 11:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- Hot Biotech Stocks Traded by Hedge Funds in First Quarter 05.16.12 | 07:05 am
- 7 Cancer Drug Stocks to Know Right Now 03.14.12 | 09:03 am
- Array BioPharma Stock Gaps Down On Today's Open (ARRY) 02.09.12 | 08:02 am
Press Releases for ARRY
- Promising Data For KRAS Mutant Advanced NSCLC Patients Presented At ASCO - Business Wire 06.04.12 | 05:06 pm
- MEK162 Shows Promising Clinical Activity In Ongoing Phase 2 Trial - Business Wire 06.04.12 | 04:06 pm
- Array BioPharma To Present At The Jefferies 2012 Global Healthcare Conference - Business Wire 05.30.12 | 03:05 pm
- Array BioPharma And Genentech's Strategic Alliance Voted Breakthrough Alliance Of 2012 - Business Wire 05.14.12 | 06:05 pm
- Liam Ratcliffe, M.D., Ph.D., Independent Director, Array BioPharma Board Of Directors (Photo: Business Wire) - Business Wire 04.30.12 | 08:04 am
- Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2012 On April 30, 2012 - Business Wire 04.23.12 | 04:04 pm
- Array BioPharma Names Howard Holden, Ph.D., Vice President Of Regulatory Affairs And Quality Assurance - Business Wire 04.16.12 | 08:04 am
- Encouraging Selumetinib Results Announced For Phase 2 Trial In Ovarian Cancer - Business Wire 04.04.12 | 09:04 am
- Array BioPharma To Present At The Cowen And Company 32nd Annual Health Care Conference - Business Wire 02.27.12 | 01:02 pm
- Array BioPharma Announces Closing Of Public Offering Of Common Stock And Exercise Of Overallotment Option - Business Wire 02.14.12 | 09:02 am
Partner Headlines for ARRY
- Array BioPharma Says Encouraging Selumetinib Results Announced for Phase 2 Trial in Ovarian Cancer - Benzinga 04.04.12 | 09:04 am
- Company News for February 10, 2012 - Corporate Summary - Zacks 02.10.12 | 10:02 am
- Biotech Stocks To Watch In 2012 - Seeking Alpha 02.06.12 | 09:02 am
- Array BioPharma Names Gwen A. Fyfe, M.D. to Board of Directors - Benzinga 01.30.12 | 04:01 pm
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 11.03.11 | 09:11 am
- Bottom Bounce for Array BioPharma - Seeking Alpha 06.29.11 | 09:06 am
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- How Array Got Its Groove Back - SeekingAlpha.com 04.28.10 | 01:04 pm
- Biotech Gets Busy With Small Company Financings - SeekingAlpha.com 04.25.10 | 08:04 am
- Array and Novartis Ink Deal - Analyst Blog - Zacks 04.22.10 | 02:04 pm
